Since 1942, therapy with radioiodine (RIT) has gained a major role in the treatment of benign thyroid disorders, notably hyperthyroidism caused by Graves' disease or toxic multinodular goitre (thyroid autonomy). In iodine deficient areas thyroid autonomy accounts for 40-50% of all cases with hyperthyroidism. RIT has become a cost-effective first-line procedure in autonomy-patients with latent o...

Controversy remains regarding the optimal dose calculation with radioiodine therapy for patients with Graves' disease. Here, we focused our analysis on data concerning the patient's pretreatment background, an empirically set dose of radioiodine and the post-treatment thyroid function, and investigated those factors that affected the outcome. The subjects consisted of 38 patients diagnosed as h...

BACKGROUND AND AIM Atherosclerosis evolves or accelerates when arteries are exposed to ionizing radiation, both early and late after exposure. Radioiodine therapy of benign thyroid disease exposes the carotid arteries to 4-50 Gy, and may thereby increase the risk of atherosclerosis. Increased risk of cerebrovascular events has been reported after radioiodine therapy. This study aimed to examine...

UNLABELLED This aim of this retrospective study was to determine the impact of glucocorticoid therapy on the effective (131)I half-life in radioiodine therapy for Graves disease. METHODS Three hundred fifteen consecutive Graves disease patients undergoing radioiodine therapy at our institution between August 2004 and January 2009 were enrolled. We investigated the influences of thyroid state ...

Background: Due to its use of ionising radiation, the field of nuclear medicine is a unique and significant part of medical diagnostics and patient treatment. The aim of this study was to assess the internal exposure of nuclear medicine employees to radioiodine 131I and technetium 99mTc as well as to assess the external exposure doses. Material and Methods: The radioiodine 131I and technetiu...

BACKGROUND Due to its use of ionising radiation, the field of nuclear medicine is a unique and significant part of medical diagnostics and patient treatment. The aim of this study was to assess the internal exposure of nuclear medicine employees to radioiodine 131I and technetium 99mTc as well as to assess the external exposure doses. MATERIAL AND METHODS The radioiodine 131I and technetium 9...

BACKGROUND This study was designed to explore the therapeutic potential of suppressing MAP kinase and PI3K/Akt pathways and histone deacetylase (HDAC) to induce the expression of sodium/iodide symporter (NIS) and radioiodine uptake in non-thyroid cancer cells. METHODS We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expressio...

BACKGROUND Selectively increased radioiodine accumulation in thyroid cells by thyrotropin (TSH) allows targeted treatment of thyroid cancer. However, the extent of TSH-stimulated radioiodine accumulation in some thyroid tumors is not sufficient to confer therapeutic efficacy. Hence, it is of clinical importance to identify novel strategies to selectively further enhance TSH-stimulated thyroidal...

BACKGROUND Thyroid cysts are rare in cats and poorly documented. OBJECTIVES To report distinguishing clinical features and treatment responses of cats with thyroid cysts. ANIMALS Forty client-owned cats. METHODS Retrospective review of medical records for cats with thyroid cysts confirmed by scintigraphy, ultrasound, magnetic resonance imaging, or necropsy at 4 referral centers between 20...

in destroying iodine-concentrating thyroid cells has been harnessed for more than 60 years in the treatment of benign and malignant thyroid diseases. Accumulated experience in large numbers of patients has confirmed the long-term safety and efficacy of radioiodine in the treatment of hyperthyroidism.1,2 Coupled with this is increasing evidence that hyperthyroidism is itself associated with sign...